In Brief: Menley & James
This article was originally published in The Tan Sheet
Executive Summary
Menley & James: Sales down slightly to $4 mil. from $4.1 mil. for the fourth quarter (ended Dec. 31); sales for the year were up slightly to $14.4 mil. from $14.3 mil. in 1996. Net income fell, with the company recording a $91,000 loss for the quarter and a $247,000 loss for the year compared to a $83,000 profit for the fourth quarter of 1996 and a $38,000 loss last year. Despite increasing competition from Rx-to-OTC switch and private label products, the company says it maintained sales by focusing on "selected unique products" and through marketing agreements for Medeva's Humibid Plus expectorant/decongestant, Rystan's Derifil internal deodorant and Ferndale's capsaicin topical analgesic (a private label version of Genderm's Zostrix)...